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Abstract 
Obesity plays a key role in the development of metabolic syndrome, but the 
underlying mechanisms still remain elusive. Factors that have been implicated 
include activation of the renin angiotensin aldosterone system (RAAS) and 
increased bioavailability of reactive oxygen species (ROS) (termed oxidative 
stress), which impact on inflammation in adipose and other tissues. 
Inflammatory processes in fat appear to be an important initiator of metabolic 
syndrome and associated cardiovascular disease. Oxidative stress and 
aldosterone levels are positively associated with adiposity. Exact mechanisms 
contributing to high aldosterone levels in obesity are unclear, but adipocytes can 
produce aldosterone, as well as ROS, phenomena that are amplified in obesity.   
 
In the present studies, we examined the relationship between ROS, aldosterone 
and adipocytes in the context of obesity. In particular we questioned whether 
ROS influence aldosterone production by adipocytes and whether these 
processes influence adipocyte function related to cell maturation, inflammation 
and fibrosis. We also explored the enzymatic source of ROS in adipocytes, 
focusing specifically on Nox isoforms, Nox1 and Nox4.  
 
To address these questions we performed in vivo and in vitro studies. Adipose 
tissue and mature adipocytes from obese db/db mice were studied. To translate 
our findings to humans, we also studied human mature adipocytes. To 
interrogate Nox1 and Nox4, we used a dual Nox1/4 inhibitor, GKT137831 
(Genkyotex S.A, Geneva, Switzerland) in vivo and in vitro studies. 
 
Aldosterone and corticosterone levels were measured by ELISA while plasma 
electrolyte, lipid and metabolic profile were assessed with an automated 
analyser. Gene expression was assessed by qPCR. Fibrosis was determined by 
picro Sirius red staining and polarized light microscopy. ROS production was 
determined by chemiluminescence, amplex Red and TBARS.  
 
Our results demonstrate that aldosterone levels were increased by 4 fold in 
plasma and 4 fold in epididymal fat culture media from db/db mice compared to 
lean mice. These effects were decreased by high dose Nox1/4 inhibitor (GKT). 
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Visceral fat from db/db mice had increased levels of oxidative stress and mRNA 
levels of inflammatory marker such as, CD206 (150%), F4/80 (600%), TNFα 
(230%), iNOS (50%), as well as collagen 6a (160%). Treatment of obese db/db 
mice with GKT did not significantly decrease fibrosis in epididymal fat but it did 
show a tendency to decrease with low dose treatment. In the perivascular fat 
from db/db mice GKT decreased the mRNA levels of pro-inflammatory markers, 
followed by an increase in mRNA levels of anti-inflammatory markers. Ang II 
stimulation of human adipocytes increased aldosterone (5 fold) and cortisol (3 
fold) production, as well as superoxide (2 fold)  and hydrogen peroxide (0.5 fold) 
levels. Aldosterone production was Nox1/4-dependent and cortisol was Nox4-
dependent. These effects are amplified in obesity and may participate in 
adipocyte dysfunction as evidenced in adipose tissue from obese db/db mice. 
Our data also suggest that oxidative stress is increased in fat from obese animals 
and may play a role in obesity-associated adipose tissue inflammation and 
potentially fibrosis. 
 
Based on these findings we conclude that in obesity Nox isoforms play an 
important role in visceral adipocyte tissue inflammation/fibrosis and aldosterone 
biosynthesis and that adipocyte Nox1/4 may be a putative therapeutic target in 
obesity-associated hyperaldosteronism and cardiovascular damage. 
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1 Introduction 
 
1.1 Obesity, cardiovascular disease and the renin-
angiotensin-aldosterone system (RAAS). 
 
Obesity results from an excess in body fat content (or adiposity). Individuals with 
adiposity are characterized as being overweight (Body mass index (BMI) 25-30) or 
obese (BMI > 30). However, the amount of excess fat stored, the regional 
distribution of fat within the body, and the related health consequences differ 
amongst obese individuals (Kopelman et al, 2000). In general, abdominal obesity 
is associated with greater cardiovascular risk that generalised obesity. 
Obesity/overweight has become a public health challenge due to the dramatic 
global increase over the last three decades. According to the World Health 
Organisation, obesity has nearly doubled worldwide since 1980 and is the 5th 
leading risk factor for death (Lim et al, 2012; WHO, factsheet). This has been 
attributed to hereditary factors, rapid economic growth and increased 
availability of high caloric food as well as lifestyle changes. Accumulating 
evidence suggests that chronic inflammation of the adipose tissue may play a 
critical role in the development of obesity-related cardiovascular and metabolic 
diseases (Furukawa et al, 2004; Cinti, 2012; Hassan et al, 2012). Numerous 
studies have shown that abdominal obesity is strongly associated with 
cardiovascular complications including hypertension, endothelial dysfunction, 
insulin resistance and type 2 diabetes (Caballero, 2003; Cade et al, 2008; 
Balistreri et al, 2010; DeMarco et al, 2014) (Figure 1.1). Due to its major role in 
obesity there is an increasing need to better understand the biology of adipose 
tissue in physiological and pathological conditions. In particular there is growing 
interest in elucidating the mechanisms that regulate adipose tissue function and 
the cross-talk with other organs, such as the heart, kidney and blood vessels.  
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Figure 1.1. Abdominal obesity is associated with cardiovascular diseases. Abdominal 
obesity is associated with multiple risk factors such as insulin resistance, oxidative 
stress and increased levels of different (adipo)cytokines and inflammatory markers, all 
of which ultimately lead to cardiovascular disorders including hypertension, endothelial 
dysfunction, and atherosclerosis. 
 
In addition of its classical role as a major storage organ for triglycerides, adipose 
tissue is a highly dynamic endocrine organ and an important metabolic sensor, 
producing numerous bioactive substances (hormones, cytokines, reactive oxygen 
species (ROS)), collectively termed adipokines (Kershaw & Flier, 2004; Hauner, 
2005; Schaffler et al, 2006; Tilg et al, 2006; Thalmann et al, 2007), that control 
systemic insulin sensitivity, immune responses and vascular homeostasis (Eringa 
EC et al, 2007). These factors can exert autocrine (on adipocyte function, such 
as adipogenesis) and paracrine actions (on other organs, including heart, kidney, 
blood vessels) (Bluher, 2012; Miao et al, 2012; Henry et al, 2012) (Figure 1.2). 
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Figure 1.2. Local and systemic effects of adipokines (Adapted from Bluher, 2012). 
Adipokines are cytokines or bioactive mediators or hormones secreted by adipose tissue. 
Some—e.g., IL-6 or TNF-α are pro-inflammatory, whilst others—e.g., adiponectin—have 
anti-inflammatory or insulin-sensitising properties. Adipokines dysregulation appears to 
play a central role in adiposity, metabolic syndrome, and the co-morbidities of obesity 
including cardiovascular diseases. 
 
However, the underlying mechanisms that control production of adipokines are 
still unclear. In obesity, adipocytes undergo hypertrophy and hyperplasia, 
leading to dysregulation of adipokine expression and secretion, which may 
promote obesity-linked metabolic disorders such as insulin resistance and 
alteration of glucose metabolism and cardiovascular diseases such as 
hypertension. These processes are associated with activation of the renin-
angiotensin-aldosterone system (RAAS) as well as oxidative stress. It has been 
reported that adipocytes possess a local RAAS, thus, producing angiotensinogen 
(AGT) and angiotensin II (Ang II), which may influence adipocyte function and 
obesity-related disorders (Engeli et al, 2000; Cassis et al, 2008). In our 
laboratory, we recently demonstrated that adipocytes are able to produce 
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aldosterone (Briones et al, 2012) and this adipocyte-derived aldosterone is 
enhanced in pathological conditions such as in obesity associated with type 2 
diabetes. Interestingly, circulating levels of aldosterone are positively correlated 
with body mass index (Rossi et al, 2008), suggesting that adipose tissue may play 
a role in aldosterone production. In addition, obesity is associated with oxidative 
stress (Furukawa, 2004). However, the interaction between adipocyte-derived 
aldosterone and ROS remains unclear. 
 
1.2 Adipose tissue biology and function 
 
Adipocytes are often considered as the ‗bad‘ non-malignant cell type in the body 
due to their role in obesity. However fat is also important for physiological 
processes, especially related to normal development and energy metabolism. 
Moitra et al (1998) demonstrated in A-ZIP/F mice, a mouse line engineered to be 
fat free, that adipose tissue has beneficial effects on growth, reproduction, 
glucose metabolism, tolerating fasting as well as preventing lipotoxicity. Similar 
effects have been reported in the human Berardinelli-Seip congenital 
lipodystrophy syndrome, a rare condition characterised by the lack of adipose 
tissue (Berardinelli, 1954). This disease is associated with severe insulin 
resistance, hyperglycaemia, diabetes mellitus, and dyslipidaemia thus underlying 
that a properly functioning AT is necessary to human health. 
 
1.2.1 Different types of fat 
Adipose tissue is composed of 50% mature adipocytes where the remaining 50% 
consists of pre-adipocytes, immune cells, fibroblasts, endothelial cells, 
mesenchymal cells, nerve fibres and connective tissues. Adipose tissue (AT) 
depots are localised in various compartments. Subcutaneous fat, localised under 
the skin, plays a ―cushioning‖ as well as an insulating role. The different visceral 
depots such as the perirenal, gonadal, epicardial, retroperitoneal, omental and 
mesenteric adipose tissues are of major physiological significance. (Roca-Rivada 
et al 2011; Tran et al, 2008). Many studies have reported that increased visceral 
fat mass is associated with metabolic dysfunction, cardiovascular disease risk 
and inflammation, while increased subcutaneous fat may be protective (Hamdy 
et al, 2006) (Figure 1.3). 
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Figure 1.3. Localisation of different fat pads (Adapted from (BAT) Nedergard et al, 
2007; (WAT) Wronska & Kmeic, 2012). Localisation of different brown (A) and white 
(B) fat pads in human body.  
 
In mammals, three types of adipocytes are present (white, brown and beige), 
with different morphologies, precursors and functions. 
1) White adipocytes, specialized in triglycerides storage, are characterised by a 
large unilocular lipid droplet which makes up 90% of the cell volume and is 
surrounded by a thin cytoplasmic rim. The little spare space only allows for a 
flattened nucleus located on the periphery and few under-developed 
mitochondria containing short and randomly organised cristae. White adipose 
tissue (WAT), the most prominent type of AT, is found in subcutaneous, 
epidydymal, perirenal and perivascular adipose tissue depots (Wronska et al, 
2012).  
2) Brown adipocytes unlike white adipocytes dissipate stored energy by 
thermogenesis and are small multilocular cells. They contain several small lipid 
droplets, a centrally located roundish nucleus and numerous mitochondria with 
well organised laminar cristae. Brown adipose depots are classically found 
around the neck, around the aorta, behind the clavicles and surrounding the 
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vertebrae. The brownish colour of brown adipose tissue (BAT) is due to the high 
number of mitochondria and vascularisation of the depot required for non-
shivering thermogenesis (Cinti et al, 2012; Nedergaard et al, 2007). Energy 
expenditure and generation of body heat are facilitated by uncoupling protein 1 
(UCP-1), a mitochondrial inner membrane protein. UCP-1 permits thermogenesis 
via mitochondrial uncoupling and oxidative phosphorylation of free fatty acids. 
Fuel oxidation is carried out through electron transport leading to an electron 
gradient that is independent of ATP synthase (Cannon & Nedergaard, 
2012/2004). Brown adipocytes demonstrate a protective role in WAT of mice 
over-expressing UCP-1 with a decrease in adiposity. UCP-1 knockout mice on the 
other hand are more sensitive to cold and prone to obesity (Enerback, 2010).  
3) Beige adipocytes, also known as brown in white or ―Brite‖, demonstrate 
characteristics found in both white and brown adipocytes. In WAT depots, beige 
adipocytes produce heat due to their expression of UCP-1. Beige adipocytes 
resemble white adipocytes when inactive, but upon activation, levels of UCP-1 
are increased to levels similar to that of brown adipocytes. Increased BAT mass 
and activity are associated with improved glucose homeostasis and decreased 
adiposity, indicating some protective role of beige adipocytes in WAT (Stanford 
et al, 2013; Guerra et al, 1998). Browning of AT depots has become an 
attractive therapeutic target to reduce obesity and its associated CVD (Tran et 
al, 2010; Stanford et al, 2013; Qiang et al, 2012). 
 
1.2.2 Adipose Tissue as an endocrine organ 
The view of adipose tissue as an inert connective tissue and storage organ for 
lipids started to shift at the establishment of its central role in energy and 
glucose homeostasis. In 1994, the Friedman laboratory discovered leptin, as the 
first adipokine, by cloning the Ob gene from genetically obese mice and its 
human homologue, thus clearly establishing the endocrine function of AT (Zhang 
et al, 1994). Since then, AT has been shown to synthesize a vast array of 
bioactive factors influencing appetite, energy balance/metabolism, insulin 
sensitivity, inflammation and vascular function (blood pressure, vascular tone). 
Adipose tissue produces and releases many pro-inflammatory and anti-
inflammatory factors, including the adipokines leptin, adiponectin, resistin, and 
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visfatin, as well as cytokines and chemokines, such as TNF-α, IL-6, MCP-1, and 
others (Figure 1.4). 
 
 
Figure 1.4. Adipocyte as fat storage and endocrine organ. H2O2: hydrogen peroxide; 
IL: interleukin; MCP-1: Monocyte chemoattractant protein 1; O2
-: superoxide anion; PAI-
1: Plasminogen activator inhibitor 1; RAS: renin angiotensin system; ROS: reactive 
oxygen species; TNF-α: Tumor necrosis factor alpha 
 
Adiponectin is a highly expressed adipokine promoting insulin sensitivity, serum 
clearance of free fatty acids (FFAs) and glucose. Decreased levels of adiponectin 
are associated with dysfunctional AT as found in obesity. Leptin also known as 
the ‗satiety hormone‘ controls energy intake and expenditure (Fenseca-Alaniz et 
al, 2007; Somoza et al 2007). By promoting lipolysis and inhibiting further lipid 
storage it preserves insulin sensitivity. Leptin also known as the satiety hormone 
binds to its receptor in the hypothalamus and supresses appetite thus permitting 
the homeostatic control of adipose tissue mass. In obesity, leptin has been 
shown to have pro-inflammatory properties by promoting phagocytic activity and 
the release of pro-inflammatory cytokines such as IL-6 and TNF-α by 
macrophages and other cell types such as adipocytes (Kristiansen et al, 2005; 
Kamimura et al, 2003; Harle P & Staub R H, 2006). On the other hand, 
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adiponectin demonstrates anti-inflammatory properties by promoting insulin 
sensitivity and inhibiting the expression of chemoattractants such as MCP-1 and 
TNF-α (Nigro et al, 2014). Kamei et al and Kanda et al  both demonstrated that 
elevated levels of MCP-1 in AT are associated with increased macrophage 
infiltration and  insulin resistance thus promoting adipose tissue dysfunction 
(Kamei et al, 2006; Kanda et al, 2006). Neutralization of TNF-α in obese fa/fa 
rats promoted insulin sensitivity and peripheral glucose uptake (Hotamisliglil et 
al, 1993). TNF-α activates inflammatory signalling cascades inhibiting insulin 
signalling leading to insulin resistance in obesity (Bernstein et al, 2006; Lo et al, 
2007) while plasma IL-6 levels are positively correlated to human obesity and 
insulin resistance (Bastard et al, 2000). 
 
1.2.3 The Renin-Angiotensin-Aldosterone System (RAAS) 
in Adipocytes 
 
1.2.3.1 The classical RAAS 
The RAAS begins with renin release by renal juxtaglomerular cells. Its secretion 
is triggered by a decrease in blood pressure or plasma salt concentration through 
tubuloglomerular feedback and by an increase in sympathetic activity. Renin is a 
key regulator of RAAS activity as it is the initial rate limiting step of converting 
angiotensinogen (AGT) into angiotensin I (AngI). The inactive angiotensin I is 
then hydrolysed to angiotensin II (AngII) by angiotensin converting enzyme (ACE) 
which is predominantly found in the lung capillaries (Figure 1.5). Ang is a potent 
vasoconstrictor regulating cardiovascular functions via AT1 (vasoconstriction) 
and the AT2 (vasodilation) receptors (Klingbeil et al, 2003; Batenburg et al, 
2005). Ang II can trigger the release of aldosterone from the adrenal glands 
leading to sodium reabsorption and water retention. Aldosterone is the classical 
end product of the RAAS cascade. It is synthesised in the zona glomerulosa of the 
adrenal glands in response to Ang II, adrenocorticotropin (ACTH) and potassium. 
 
1.2.3.2 The RAAS in adipose tissue 
In addition to the classical RAAS, there is a rich tissue RAAS, where Ang II and 
aldosterone are produced locally, as extensively reviewed by Marcus et al 
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(2013). Growing evidence indicates that adipose tissue also has a dynamic RAAS. 
The presence of a local RAAS system in AT was first identified by Campbell et al 
in 1987 by demonstrating AGT gene expression in brown AT and mesenteric fat. 
It is now known that the AT contains all the RAAS components, at least at the 
mRNA level. The exact function of the RAAS in AT is unclear, but active AT may 
contribute to local production of Ang II and aldosterone, which could influence 
adipocyte function in an autocrine manner or regulate surrounding tissue, such 
as vessels, in a paracrine manner. Briones et al recently demonstrated that 
adipocytes have all the enzymatic machinery to synthesize aldosterone, an 
effect exacerbated in obesity and diabetes (Briones et al, 2012). Moreover 
adipocytes possess functionally active mineralocorticoid receptors, through 
which aldosterone signals. 
 
 
Figure 1.5. Adipose Renin-Angiotensin-Aldosterone System. Adipocytes possess all the 
components of the renin-angiotensin-aldosterone system (RAAS). Therefore adipocytes 
can produce angiotensinogen, angiotensin II and aldosterone, which can have autocrine 
and paracrine effects (on vascular function for example). Ang I: Angiotensin I; Ang II: 
Angiotensin II; ACE: angiotensin converting enzyme; Cyp11b1/2: Steroid 11β-hydroxylase 
or cytochrome P450, family 11, subfamily B, polypeptide 1/2; 11βhsd1/2: 11β-
hydroxysteroid dehydrogenase type 1/2; MR: mineralocorticoid receptor; PVAT: 
perivascular adipose tissue.  
 
1.2.3.3 Aldosterone  
Aldosterone exerts its effects via the mineralocorticoid receptor (MR). While the 
well-described ―classical‖ effects of aldosterone on transepithelial Na transport 
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are mediated by MR present in epithelial cells, MR has been shown to be present 
in a many other cell types including adipocytes. Activation of MR appears to 
have important roles in adipose tissue including differentiation of pre-adipocytes 
into mature adipocytes and promotion of a pro-inflammatory state via induction 
of cytokines including TNF-α, monocyte chemotactic protein-1 (MCP-1), and IL-6 
in WAT, while decreasing the thermogenic activity and lowering uncoupling 
protein 1 (UCP1) transcription in BAT (Zennaro et al, 2009). MR mRNA expression 
was increased in obese db/db mice (Hirata et al, 2009). 
 
Aldosterone acts via genomic and non-genomic signalling pathways. Classic 
genomic pathways involve binding to the cytosolic mineralocorticoid receptors 
(MR) followed by the translocation to the nucleus, and transcription of effector 
protein involved in regulating of potassium and sodium balance in the kidney 
epithelial cells (Funder, 2006). Non-genomic pathway occurs within seconds and 
does not act on sodium-potassium homeostasis. It is involved in rapid activation 
of tyrosine kinases and subsequent downstream activation of ERK1/2, Rho 
Kinase, and PKC in association with increased cytosolic calcium and generation 
of ROS (Grossman & Gekle, 2009). MR is expressed in classical target tissues 
including kidney, colon and sweat glands. However, studies from the past two 
decades reported that MR is also expressed in other organs such as the heart, 
vessels, adipose tissue and macrophages, where the role of the hormone remains 
unclear, although it may have a pro-fibrotic and pro-inflammatory role (Nguyen 
Dinh Cat & Jaisser, 2012). 
 
In 1987 Arriza et al demonstrated by cloning the human MR that it had the same 
affinity for both aldosterone and corticosterone/cortisol. These results led to 
the question as to how aldosterone acts via the MR when the 
corticosterone/cortisol levels are 100- to 1000-folds greater. This disparity is 
maintained in hyperaldosteronism. It was found that corticosterone/cortisol 
could be inactivated and activated by 11β-hydroxysteroid dehydrogenase types 2 
and 1 (11β-HSD1 and HSD2) respectively (Funder et al, 1988; Edwards et al, 
1988). The selective MR signalling via aldosterone in epithelial cells is due to the 
high levels and activity of 11βHSD2. Importantly, aldosterone/MR signalling 
selectivity is carried out differently in non-epithelial tissues.  
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1.2.3.4 Effects of aldosterone on adipocyte function 
In T37i cells, a brown adipocyte cell line, Zennaro et al (1998) first established 
that aldosterone promotes differentiation of pre-adipocytes towards mature 
adipocytes with a white adipocyte phenotype. Observed changes include the 
induction of lipid accumulation and elevated adipocyte differentiation markers:  
peroxisome proliferator-activated receptor-gamma (PPAR-γ) and adipocyte 
specific fatty acid binding protein 2 (aP2). Viengchareum et al (2001) showed 
the inhibitory capacity of aldosterone on the expression and function of UCP-1 
the protein responsible for non-shivering thermogenesis. Armani et al (2014) also 
showed that aldosterone/MR signalling blocked browning of WAT. Thus, 
aldosterone promoted brown adipocyte differentiation while shifting towards a 
white adipocyte phenotype by promoting lipid storage and inhibition of energy 
expenditure. This could lead to the loss of the beneficial aspect of BAT in 
chronic MR over activation. Aldosterone/MR signalling promotes differentiation 
in 3T3-L1, a mouse white adipocyte cell line; however GR signalling by 
glucocorticoids can also elicit adipocyte differentiation. Hence, the role of MR 
and GR in adipocyte differentiation is contentious. Caprio et al (2007) showed 
that downregulation of MR and not of GR inhibits adipocyte differentiation while 
Lee and Fried (2014) argue that GR alone participates in the differentiation 
process. 
 
1.2.4 Adipose Tissue and reactive oxygen species (ROS) 
ROS are by-products of the reduction of oxygen to water. Originally these 
molecules were thought to be deleterious however they now have been accepted 
as having beneficial effects under physiological levels. To maintain physiological 
levels they are controlled by a tight regulatory system also known as the oxidant 
defence system. ROS are produced by many sources including macrophages, 
mitochondria, xanthine oxidase, uncoupled nitric oxide synthase and 
nicotinamide adenine dinucleotide phosphate (NADPH) oxidases (Nox). 
Interestingly, Noxes are the only source of ROS where they are not formed as a 
by-product. The physiological role of ROS involves both regulation of 
transcription factors and induction of host defence mechanisms (Bedard et al, 
2007) ROS also act as secondary messengers influencing MAP kinases, protein 
tyrosine kinases, protein phosphatases, and ion channels that regulate cell 
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proliferation, apoptosis, migration and fibrosis, inflammation, vascular tone and 
angiogenesis. Adipocytes have been shown to produce ROS, in response to Ang II 
and aldosterone (Kurata et al, 2006). Adipocyte-derived ROS may play a role in 
promoting inflammation in the context of obesity, commonly associated with 
oxidative stress (increased ROS bioavailability). 
 
1.2.4.1 Nox isoforms in adipocytes: The Structure of Nox1, 2 and 
4 
One of the major enzymatic sources of ROS are the NADPH oxidases (Nox) Seven 
isoforms have been identified: Nox1-5 and Duox1 and Duox2. Here we will focus 
on the Noxs that have been identified in AT, namely Nox1, 2 and 4 (in mice) and 
Nox 1, 2, 4 and 5 in humans (Figure 1.6). 
 
Figure1.6. Structure of NADPH oxidases localized in mouse AT. 
The NADPH oxidase (Nox) family shares a core structure consisting of six 
transmembrane protein domains, four heme histones, a long COOH terminus, 
FAD binding domain and an NADPH binding site. Each Nox seems to use specific 
combination subunits required for the activation of the core transmembrane 
complex. Nox1, 2 and 4 are membrane complexes which require p22phox subunit 
for their function. The role of p22phox is varied as it can serve to stabilise the Nox 
subunit as well as being the docking site of regulatory subunits (Ambasta et al, 
2004). The production of ROS by Nox1 and Nox2 requires the presence of 
regulatory subunits and of a small RAC GTPase. The regulatory subunits of Nox2 
are p47 phox, p67 phox and p60 phox that form a complex with small RAC GTPase and 
the nox2/p22 phox heterodimer. Once the complex is formed it is active and 
results in the translocation of the complex to the plasma membrane. The 
regulatory subunits of Nox1 are composed of NoxO1 and NoxA1 which are 
homologues of p47phox and p67phox respectively with a small RAC GTPase. Nox2 
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also known as the phagocytic Nox for its high expression and vital role in 
phagocytic cells permits an immune defence response. When activated, 
phagocytic Nox2 permits the production of large amounts of ROS which are used 
to kill microbes. Nox2 is also expressed in adipocytes just as is Nox1 but their 
role in the AT has not yet been established. Unlike Nox1 and 2, Nox4 does not 
need any regulatory subunit only p22phox is required for ROS production. Poldip2 
can bind to the Nox4/p22phox heterodimer to enhance Nox4 activity thus 
increasing the ROS generation (Lyle et al, 2009).  
Noxes produce superoxide ions (O2
-) which are highly reactive and short lived 
free radicals that are converted to the more stable and membrane permeable 
hydrogen peroxide (H2O2) by superoxide dismutase (SOD). Interestingly, Nox4 is 
constitutively active and thought to generate the basal ROS levels. Also, it 
generates H2O2 rather than O2
- but the underlying reasons are unknown. Current 
theories include that the terminal heme binding site inside the transmembrane 
allows direct production of H2O2 or possibly the SOD is located close to the exit 
of the six transmembrane protein domains to convert O2
- to H2O2.  
 
1.2.4.2 Redox signalling and physiological role of Noxes in 
adipocytes 
Some studies have underlined the role of ROS in adipocyte differentiation and 
redox-sensitive mechanisms by modulating adipocyte signalling with 
physiological ROS levels. Adipocyte differentiation is the transition of pre-
adipocyte to mature adipocytes which can store the excess lipid and prevent the 
present adipocytes from becoming hypertrophic. Adipocytes increase in size as 
they store lipids however there is a limit as to how much they can store. Several 
studies propose ROS as a promoter for adipocyte differentiation. 3T3-L1 cells 
show an increase in ROS production during differentiation but differentiation 
was inhibited by antioxidants (Furukawa et al, 2004). Nox4 is a potential 
regulator of differentiation as it is a constitutively active enzyme producing H2O2 
along with its high mRNA gene expression in pre-adipocytes (Mouche et al, 
2007). Inhibition of Nox4 with siRNA blocked insulin signalling for the terminal 
differentiation of adipocytes (Schröder et al, 2009). These in vitro studies 
suggest that Nox4 plays a role in adipocyte differentiation however this still 
awaits confirmation. 
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1.2.5 AT regulation of vascular reactivity 
In 1991, Cassis and Soltis demonstrated that ―perivascular adipose tissue (PVAT) 
significantly influences vascular responsiveness‘‘ underlying the role of the 
adipose tissue on vascular regulation. The vascular contractility of blood vessels 
pre-incubated in PVAT conditioned media demonstrated the existence of 
adipocyte derived relaxation factor (ADRF) (Soltis et al, 1991). PVAT was shown 
to promote the release NO and eNOS derived NO thus enhancing vasodilatation 
an effect lost in obesity. Endothelial nitric oxide synthase (eNOS)-derived nitric 
oxide (NO) stimulates endothelium-dependent relaxation of the smooth muscle 
cells by activation of soluble guanylyl cyclase and hyperpolarization (Ortega et 
al, 2010/2009). In addition to ADRF, other PVAT-derived factors may modulate 
vascular tone including, pro- and anti-inflammatory adipokines, aldosterone and 
ROS. In obesity, adipocyte- and endothelium- derived relaxing factors are 
impaired while the adipocyte-derived contractile factors, from the perivascular 
adipose tissue (PVAT), are enhanced thus promoting endothelial dysfunction 
(Maenhaut et al, 2011; Boyden et al, 2012). 
 
1.3 Adipose tissue in Obesity 
In obesity, the endocrine function of adipocytes is modified with increased 
production of leptin, resistin, FFA and pro-inflammatory cytokines while 
adiponectin production is reduced. Obesity is associated with chronic low grade 
inflammation of AT where both adipocytes and macrophages contribute to local 
inflammation and oxidative stress. The increased release of MCP-1 in obesity by 
adipose tissue leads to a significant increase in inflammatory monocyte 
infiltration. These monocytes undergo polarization to M1 macrophages, 
classically activated (pro-inflammatory) instead of M2a macrophages, 
alternatively activated (anti-inflammatory), which further increases AT 
inflammation and dysfunction (Lumeng et al, 2007, 2008). WAT and BAT are 
highly vascularized tissues whose physiological function, expansion and 
adipocyte differentiation require angiogenesis. Effective vascular remodeling 
and maintained blood flow are crucial to the adipose tissue as it permits the 
supply of oxygen, nutrients, immune cells, bone-marrow derived stem cells, 
growth factors and hormones needed for normal functioning. However in 
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obesity, the AT becomes hypertrophied and hypoxic which further promotes 
adipocyte dysfunction (Wood et al, 2009; Sun et al 2011). 
 
Obese individuals have excess collagen I, III and VI deposition in adipose tissue 
contributing to adipose tissue fibrosis (Henegar et al 2008; Divoux et al 2010). 
Fibrosis is defined as an excess of collagen depots promoting pathological 
conditions and is a hallmark of chronic tissue damage.Nox4 was found to play a 
role in hepatic and lung fibrosis and this may also occur  in the AT (Aoyama et 
al, 2012; Jarman et al, 2014). Adipose tissue fibrosis may be a factor linking 
obesity to cardiovascular diseases along with tissue inflammation. 
 
Due to its role as a major energy storage organ the AT possesses an incredible 
plasticity and thus undergoes constant remodeling. Along with fibrosis and 
collagen deposition, the extracellular matrix (ECM) undergoes remodelling. 
Adipose tissue function is regulated by the interaction between collagen, cells 
and the ECM (Mariman & Wang, 2010). The ECM is a fibrillar network comprising 
collagen, fibronectin and proteoglycans. Matrix metalloproteinases (MMP) are 
enzymes specific for the degradation of ECM components inhibited by tissue 
inhibitors of metalloproteinases (TIMP). ECM pathological remodelling is due to 
an imbalance between production and degradation as found in AT fibrosis 
(Mariman & Wang, 2010). 
 
1.3.1 Role of oxidative stress 
Elevated ROS levels and decreased antioxidants induce oxidative stress, which 
leads to tissue injury and inflammation. Oxidative stress also correlates with fat 
accumulation in humans and animal models. Oxidative stress, due in part to 
increased activation of Noxs, in obesity can lead to irreversible oxidative 
modifications that induce adipocyte dysfunction. Nox4 activation promotes a 
pro-inflammatory phenotype by the increase of monocyte chemotactic factor 
genes expression in 3T3-L1 cells (Han et al, 2012). This is similar to the effects 
found in aldosterone/MR signalling, which may occur via ROS production. The 
levels of Nox2 are increased in AT in obesity due to the elevated macrophage 
infiltration and participates in promoting ROS as well as cytokine synthesis. Nox1 
expression is also increased in obesity. Nox1 is sometimes referred to as the 
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pathological Nox, due to its increased expression being associated with a variety 
of diseases including diabetes and hypertension (Matsuno et al, 2005; Gray et al, 
2013) 
 
1.3.2 Role of MR signalling 
Emerging evidence supports a shift in our understanding of the crucial role of 
the elevated circulating levels of aldosterone in promoting insulin resistance and 
resistant hypertension. Aldosterone enhances tissue generation of ROS and 
systemic inflammation. This increase contributes to impaired insulin signalling, 
reduced endothelial-mediated vasorelaxation, and associated cardiovascular and 
renal structural and functional abnormalities (Whaley-Connell et al, 2010). As 
mentioned previously, AT releases a soluble active compound that promotes the 
release of aldosterone form the adrenal gland. The release of this unknown 
compound is increased in obesity thus increasing the release of aldosterone. 
Adipose tissue itself also shows an increase in aldosterone synthesis in obesity. 
Interestingly MR mRNA expression was increased in obese db/db mice leading to 
over-activation of MR in obesity (Guo et al, 2008; Hirata et al, 2009). MR 
activation promotes proliferation, inflammation and fibrosis in many organs such 
as the heart, kidneys, and the vasculature via ROS production (Park et al, 2008; 
Callera et al, 2005; Hirata et al, 2009). Chronic low grade inflammation 
associated with overproduction of ROS in fat tissue contributes to the 
development of metabolic syndrome. Aldosterone may increase ROS production 
in AT by increasing the expression of Nox subunits as shown in studies on other 
tissues (Park et al, 2008). 
 
It is well established that aldosterone promotes inflammation in a variety of 
tissues and that chronic low grade inflammation is key in obesity alongside 
imbalanced production of bioactive factors by adipocytes. A study on obese mice 
showed increased expression of inflammatory adipokines TNF-α and MCP-1 and 
reduced expression of adiponectin and PPARy compared to the lean control were 
reversed by MR inhibition (Guo et al, 2008). Another study on two genetic 
models of obesity, ob/ob and db/db, by Hirata et al (2009) demonstrated that 
MR inhibition by eplerenone improved insulin sensitivity and reduced ROS 
production, restoring the balance in adipokine synthesis. In 3T3-L1 cells, 
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stimulation with aldosterone and H2O2 increased pro-inflammatory 
adipo(cyto)kines and TBARS which was blocked by eplerenone. Interestingly, 
H2O2 in 3T3-L1 cells increased ROS production while decreasing antioxidants 
catalase, Cu and Zn-SOD gene expression (Hirata et al, 2009). This indicates that 
ROS can modulate Nox and antioxidant expression promoting oxidative stress in 
disease state. This study also indicates that MR activation promotes ROS 
production. 
 
In obesity macrophages in a polarized state play a key role in inflammation and 
adipocyte dysfunction. Interestingly macrophages also express MR on their 
surface. Macrophages are classically activated (M1) when exposed to aldosterone 
and alternatively activated (M2) with the MR inhibitor eplerenone but a GR 
antagonist had no effect (Usher et al, 2010). Consequently, MR activation has 
the capacity to increase AT inflammation as well as oxidative stress (Marzolla et 
al, 2014). A paradoxical study by Kuhn et al (2014) showed protective effects 
against obesity in transgenic mice that overexpress MR specifically in 
macrophages upon high fat diet (decrease in fat mass, smaller adipocytes, 
improved glucose tolerance). Furthermore, co-cultured macrophages and 
adipocytes from these transgenic mice showed a decrease in adipocyte 
differentiation. These results suggest that MR is a pro-adipogenic and pro-
inflammatory effector mediating effects on adipocyte development and 
functions. 
 
1.4 Rationale for the studies. 
Despite the growing evidence that oxidative stress, hyperaldosteronism and 
inflammation are associated with obesity and metabolic and cardiovascular 
disease, molecular mechanisms linking these processes still remain unclear. In 
the present studies, we examined the relationship between ROS, aldosterone 
and adipocytes in the context of obesity. In particular we questioned whether 
ROS influence aldosterone production by adipocytes and whether these 
processes influence adipocyte function related to cell maturation, inflammation 
and fibrosis. We also explored the enzymatic source of ROS in adipocytes, 
focusing specifically on Nox isoforms, Nox1 and Nox4. 
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1.5 Aims and hypothesis of the study 
 
Overall hypothesis 
In obesity associated with metabolic syndrome (obesity-MS), adipocytes 
generate aldosterone through Nox1/4-dependent processes, contributing to a 
pro-inflammatory and pro-fibrotic adipose phenotype (Figure 1.7). 
 
Specific aims. 
To address our hypothesis, 4 specific aims were proposed: 
1. To evaluate whether obesity/metabolic syndrome is associated with 
hyperaldosteronism and increased adipocyte-derived aldosterone through 
processes that involve Nox1/4; 
2. To determine whether increased Nox1/4-derived ROS influences 
aldosterone biosynthesis by stimulating aldosterone synthase in 
adipocytes; 
3. To assess whether aldosterone and ROS promote adipokine production and 
adipogenesis and if this is increased in obesity;  
4. To elucidate whether redox-sensitive processes and aldosterone promote 
a pro-inflammatory and pro-fibrotic adipose phenotype.  
 
Experimental approach 
To address these aims, we performed studies in adipose tissue and mature 
adipocytes from obese mice that also have features of metabolic syndrome 
(db/db mice). To translate our findings to humans, we also studied 
differentiated human adipocytes. A dual Nox1/4 inhibitor, GKT137831, and other 
Nox/ROS modulators were used to elucidate the role of Nox isoforms.  
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Figure 1.7. Hypothetical representation of the link between obesity, oxidative stress 
and aldosterone. Nox1/4-derived ROS play a central role in obesity by regulating 
aldosterone production by adipocytes and are an early instigator of metabolic 
syndrome. Redox state in adipose tissue is a potentially useful therapeutic target for 
obesity-associated metabolic syndrome. HRE: Hormone responsive element; MR: 
Mineralocorticoid receptor; NOX: NADPH oxidase; ROS: reactive oxygen species 
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2 Materials and Methods 
We tested our hypothesis using an in vivo and in vitro approach.  
 
2.1 In Vivo 
2.1.1 Mice  
In vivo studies were performed in obese db/db mice treated with GKT137831 a 
Nox1/4 inhibitor provided by Genkyotex S.A, Geneva, Switzerland (Page et 
al,2008). The animal studies were conducted by Drs Nguyen Dinh Cat and 
Montezano in the Touyz lab in Ottawa (Canada), before moving to Glasgow. The 
study was approved by the Animal Ethics Committee of the University of Ottawa. 
Tissue from the animal studies were processed and studied in Glasgow. 8 weeks 
old male B6.BKS(D)-Leprdb/J (Stock Number 000697) (or obese db/db mice) and 
control were C57BL/6J heterozygotes from the colony (or lean db/+ control) 
mice were purchased from Jackson Laboratories (Maine, USA) and housed 
individually at ambient temperature under 12h light/dark cycles. Animals had 
free access to drinking water and A04 normal diet. Obese and lean animals were 
separated into three groups: none treated, low dose treatment with Nox1/4 
inhibitor and high dose treatment with Nox1/4 inhibitor each comprising ten 
mice. 
 
2.1.2 Treatment 
The db/+ (lean) and db/db (obese) mice, at 10 weeks, were fed with a low (20 
mg/kg/day) or high dose (60 mg/kg/day) of dual Nox1/Nox4 inhibitor 
(GKT137831), for 16 weeks. The animals were sacrificed by decapitation. After 
treatment, adiposity was determined and plasma samples obtained and stored at 
-80oC for determination of aldosterone and corticosterone concentrations Tissues 
were harvested for further analysis. 
 
2.2 Biochemical assays 
Blood samples were collected at the end of the study by cardiac puncture, under 
anaesthesia. Glucose, total triglycerides, cholesterol, LDL and HDL were 
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determined in plasma samples using an automated analyser (Synchron CX5 PRO; 
Beckman and Fullerton). 
 
2.3 Histology 
Epididymal visceral adipose tissue (EVAT) from db/+ and db/db mice was 
removed and drop-fixed in 10% formalin solution, left for 48 hours at room 
temperature. For embedding, the tissues were dehydrated through a series of 
graded ethanol baths to displace water. They were then infiltrated with wax and 
finally embedded in wax blocks. EVAT tissue was sectioned to 5μm slices using a 
microtome. Fibrosis was assessed using Picrosirius red staining. Sections were 
stained momentarily with Weigert‘s haemotoxylin to stain the nucleus (Sigma-
Aldrich), washed then stained in 0.1% picrosirius red solution under dark 
conditions. Fibrosis/collagen content was determined from five to eight fields of 
view on each section using ImageJ. Fibrosis was further assessed by use of 
polarised microscopy on the Picrosirius red stained slides in order to 
differentiate between older and recently made collagen. The results were 
analysed from five to eight fields of view on each section using ImageJ and Cell-
D. 
 
2.4 Cell Culture 
2.4.1 Cultured mouse mature adipocytes 
Mouse abdominal EVAT was obtained from male obese db/db and their 
littermates lean control (db/+) mice. Adipose tissue was cleaned of blood vessels 
and fibrous tissue and thoroughly minced with scissors in DMEM/F12 medium. 
The tissue was digested with collagenase type I (Worthington Biochemical 
Corporation, Lakewood, NJ) (0.5 mg/mL/g tissue) in Krebs-Ringer HEPES buffer 
pH7.4 (in mmol/L: 125 NaCl, 4.8 KCl, 0.5 NaH2PO4, 1.2 MgSO4, 2.6 CaCl2, 25 
HEPES, 2 NaHCO3, 5.5 Glucose) containing 1% BSA for 20-30 min in a rotating 
shaker at 37oC. After digestion, the same volume of DMEM/F12 was added to the 
sample mixture which was filtered through a 200μm mesh and centrifuged at 50 
g for 5 min. The pellet was discarded. The floating mature adipocyte fraction 
was transferred into a new tube containing DMEM/F12 and centrifuged (50 g, 5 
min). The floating mature adipocytes fraction was washed in DMEM/F12 twice. 
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After the last centrifugation, the mature adipocytes were placed in 500μL of 
DMEM containing 15 mmol/L HEPES pH7.4, 17 nM insulin and 1% FBS and 
incubated in 5 % CO2, at 37°C for 24 hr. After 24 hrs, culture media were 
collected and stored at -80°C until aldosterone and corticosterone 
concentrations determinations. Cells were washed with 1X PBS and collected 
with 250 mL of Trizol for RNA extraction. 
 
2.4.2 Cell lines  
SW872 cells (pre-adipocytes from a human liposarcoma cell line) were purchased 
from the American Type Culture Collection (ATCC, Manassas, VA). SW872 cells 
were cultured on DMEM low glucose supplemented with 10% fetal bovine serum 
(FBS) and 1% Pen/Strep in 5% CO2, at 37º C. 
 
2.4.3 Cell Culture and Passage 
Cell culture was performed under sterile conditions. Cells were cultured in 
normal growth serum at 37oC in 5% CO2 and 95% air. Cells were cultured until 
70% confluence for differentiation protocol and 90% confluence for passage or 
cryopreservation. The medium was removed and the cells washed with 1% 
phosphate buffer saline (PBS) which was also discarded. The cells were detached 
by adding 0.025% trypsin (Gibco) to cell flasks and incubated at 37oC for 5mins. 
Cells were resuspended in normal growth medium, to inactivate the trypsin, and 
then centrifuged for 3min at 200 g. The supernatant was discarded and the cell 
pellet resuspended in normal growth medium and placed in appropriate 
containers. 
 
2.4.4 Cryopreservation 
Cells were stored using a freezing medium containing the normal growth medium 
supplemented with 5% of dimethyl sulphoxide (DMSO) to prevent crystal 
formation in the freezing process. Cells were stored at -80oC or liquid nitrogen. 
For resuspension, cells were rapidly thawed in a water bath at 37oC and added 
to a sterile tube with growth media and centrifuged for 3min at 200 g in order to 
remove DMSO. The supernatant was removed and the cells resuspended into a 
certain volume of normal growth medium and transferred to a T25 flask. 
Sarah Even   35 
 
 
2.4.5 Differentiation protocol for SW872 preadipocytes 
At 80% confluence, SW872 were subjected to a differentiation process by 
culturing them in DMEM supplemented with 10% FBS, 0.5 mmol/L 3-isobutyl-1-
methylxanthine (IBMX, Sigma Chemical Co), 0.25 µmol/L dexamethasone, and 1 
μmol/L insulin for 2 days. Medium was replaced by DMEM supplemented with 10% 
FBS, and 1 μmol/L insulin for an additional 2 days. Subsequently, the medium 
was replaced by DMEM containing only 10% FBS for 4 days. At the end of the 
differentiation period, the cells exhibited adipocyte morphology and 
differentiated human SW872 adipocytes were maintained in DMEM supplemented 
with 1% FBS and antibiotics overnight before stimulation. 
 
2.4.6 Cell stimulation protocols 
SW872 adipocytes were stimulated with 10 nmol/L Ang II for 24hrs in the 
presence and in absence of various ROS inhibitors: Nox1/4 inhibitor (1 µmol/L 
GKT137831), Nox1/Nox2 inhibitor (1 µmol/L ML171), and SOD mimetic (10 
mmol/L Tempol). After stimulation, culture media were collected and kept at -
80°C for aldosterone and cortisol determinations. Cells were washed with 1X PBS 
further processed for protein extraction. 
 
2.5 General Molecular biology 
2.5.1 RNA extraction 
Total RNA was extracted from EVAT and perivascular mesenteric (PVAT) adipose 
tissues from obese and lean mice treated or not with Nox1/4 inhibitor and from 
SW872 cells with 750 μL and 250 μL Trizol, respectively (Invitrogen), following 
manufacturer's instructions. Mouse adipose tissues were homogenised using lysis 
tubes, containing micro-beads and a lysing homogenizer (Precellys 24, Bertin 
technologies, UK) programmed at for 2x20sec at 5000 rpm. To retrieve the RNA 
from homogenised samples, 200μL chloroform was added after homogenisation. 
After 2min at RT, samples were centrifuged at 12000g for 15min at 4°C. Aqueous 
phase was collected and transferred to new tubes to which 500μL isopropanol 
was added to precipitate nucleic acids. Samples were mixed, and after 15min at 
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RT were centrifuged for 10min at 1200g at 4°C. Supernatants were removed, 
and the pellets washed with 500 μL of 75% ethanol and centrifuged at 7500g for 
5min at 4°C. Supernatants were removed and the pellets dried at 37°C. Samples 
were resuspended in 20-30 μL of RNAse free water depending on pellet size. RNA 
concentrations were measured using Nanodrop ND-1000 or spectrophotometer at 
260nm absorbance. Averages of duplicate or triplicate readings were taken for 
each sample. Samples were stored at -80°C until next step. 
 
2.5.2 RNA purification and reverse-transcriptase reaction 
To ensure no DNA was present in samples, total RNA samples (10 μg) were 
treated with DNase I with DNA-free kit as described by the manufacturer 
(Ambion). DNase treated RNA (1 μg) was reverse-transcribed with a high capacity 
cDNA reverse transcription kit (Applied Biosystems) using 10X Reverse 
Transcription Buffer, 25XdNTP Mix, 10X Random Primers, RNase inhibitor, 
MultiScribe Reverse Transcriptase and nuclease free water. Reverse transcription 
was performed in a thermocycler (DNA Engine Tetrad Peltier thermocycler (MJ 
Research, PTC-225) using the following parameters: 10 mins at 25°C, 120 mins at 
37°C, and 5 mins at 85°C. Samples were stored at -20°C.  
 
2.5.3 Quantitative real time Polymerase Chain Reaction (PCR) 
Real time PCR was carried out on a HT Fast Real-Time PCR machine with 
application of the 384-Well Block Module (Applied Bio systems, Life 
Technologies) using gene specific primers to quantify the relative abundance of 
each gene with FAST SYBR Green Master Mix (Applied Biosystems) as the 
fluorescent molecule. Primers used were designed using the software Primer 3. 
PCR was performed in duplicate for each sample using a PCR Master Mix 
containing nuclease free water, 300 nmol/L primers, and 3 μL template cDNA in 
25 μL total volume. PCR conditions consisted of an activation step of the Hot 
Gold Start Taq DNA polymerase (95°C) for 10 min, followed by 40 cycles of 10 
secs at 95°C (denaturation step) and 1 min at 60°C (primer annealing, 
extension, and fluorescence acquisition). Serial dilution of pooled cDNA was used 
in each experiment to assess PCR efficiency. F-box and leucine-rich repeat 
protein-10/Importin-8 (Fblx10/Ipo8), Ubiquitin-conjugating enzyme E2 (Ubc) or 
hypoxanthine guanine-phosphoribosyl-transferase (Hprt) housekeeping genes 
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were used as the reference gene for normalisation. The relative copies number 
of the target genes were calculated with the 2(-ΔΔCt) method, after assessment 
that PCR efficiency was 100%. 
 
2.6 Enzyme immunoassays: Aldosterone, corticosterone 
and cortisol measurements 
Aldosterone (#10004377), corticosterone (#500651) and cortisol (#500360) 
concentrations were determined in plasma and the study was approved by the 
Animal Ethics Committee of the University of Ottawa. Mature adipocytes from 
db/db and db/+ mice as well as CCM of stimulated SW872 cells by enzyme 
immunoassay (EIA) (Cayman Chemical) according to the manufacturer´s 
instructions. CCM from adipocytes was concentrated in a speed vacuum system 
(Vacufuge Eppendorf). These immunoassays are based on a competition between 
the steroid hormone of interest (aldosterone will be used as an example here) 
and Ache (aldosterone-acetylcholinesterase conjugate, a tracer). Sample 
aldosterone was first extracted to prevent interference by other steroid 
hormones. The plate used was pre-coated with a goat polyclonal antibody to 
which was added AChE and either standard or sample. The sample and tracer 
compete to bind to the aldosterone monoclonal antibody which binds to the goat 
polyclonal antibody attached to the bottom of the wells. The plate was then 
washed and the Ellman‘s reagent was added producing a yellow colour read with 
a spectrophotometer (Dynex, Magellan Bioscience) at 412 nm absorbance. The 
intensity of the colour was proportional to the amount of bound AChE and 
therefore inversely proportional to the amount of sample aldosterone present in 
the wells. A standard curve was derived and non-conditioned medium as well as 
blank measurement of non-conditioned medium was subtracted from all samples  
 
2.7 Protein concentration  
SW872 adipocytes were lysed with appropriate buffer depending on technique 
used. Protein concentrations were determined using a detergent compatible 
(DC) Protein Assay kit according to the manufacturer‘s instructions (Bio Rad). 
Serial dilutions of albumin protein ranging from 0.125mg/ml to 6mg/ml were 
prepared (in lysis buffer) to make a concentration standard curve for each assay. 
DC mixture was prepared by mixing reagents A and B (provided) at ratio of 1:8 
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(25μl and 200μl respectively). For every ml of reagent A used 20μL of reagent S 
was added (used when detergent is present in lysis buffer). To a 96-well plate, 
in duplicate, were added 5μl of the albumin standards / protein samples / lysis 
buffer (blank) to which were added the DC reagent mix. Plates were 
subsequently incubated at 37°C for 15min. The DC assay is based on the Lowry 
assay where copper reduction by proteins and Folin reduction by the copper-
protein complex producing a blue colour. The optical density (OD) of the colour 
is directly proportional to the quantity of protein in a sample. Absorbance at 
750nm was determined using a Wallac Victor2 plate reader (Wallac, Turku, 
Finland). The average value of the two replicates was calculated. Concentration 
of protein in each sample was assessed from the linear equation of the standard 
curve and the degree of dilution. 
 
2.8 ROS measurements 
2.8.1 Superoxide ions levels measurements 
Superoxide measurement was evaluated using lucigenin-dependent 
chemiluminescence (LgCL) and the experiments were performed in SW872 cells 
protein lysates. The SW872 cells were stimulated according to protocol and 
scraped on ice using 70μl of ROS lysis buffer (Drugs and solutions section). Basal 
O2
- levels were measured with 50 μl sample with 100μl ROS Buffer in a white 96 
well plate. 75μl of lucigenin mix (lucigenin 5µM) were added away from light. 
Basal O2
- signal was measured using the AutoLumat LB 953 microplate 
luminometer (Berthold Technologies, Bad Wildbad, Germany) and the Simplicity 
4.2 software. O2
- production was measured by adding 100 μM NADPH to each 
sample in microplate luminometer machine. The basal O2
- reading was 
subtracted from the active O2
- production and normalised to protein 
concentration.  
 
2.8.2 Measurement of hydrogen peroxide levels 
Hydrogen Peroxide levels were evaluated in PVAT, EVAT, PVF and SW872 cells 
using the Amplex Red Hydrogen Peroxide/Peroxidase assay kit (Invitrogen 
#A22188) the experiments were performed in adipose tissue and SW872 cell 
protein lysates, according to the manufacturer‘s instructions. Amplex red 
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reagent in combination with horse radish peroxidase HRP reacted to the 
presence of H2O2 producing the red fluorescent oxidation product, resofurin 
(Figure 2.1). 
 
Figure 2.1. Measurement of hydrogen peroxide levels 
 
In a clear 96 well plate 50μl of sample protein lysate was added with 50μl of 
amplex red and HRP working solution as advised in the kit manual. The plate was 
incubated in the dark for 30mins at RT and read at 560nm absorbance using a 
plate reader (Dynex, Magellan Bioscience). The results were analysed with the 
H2O2 standard curve as described in the kit manual and normalised to protein 
concentration. 
 
2.8.3 Determination of TBARS levels  
Malondialdehyde (MDA) is a natural result of lipid peroxidation which can be 
used as an indirect measurement of systemic oxidative stress. Lipid peroxidation 
was evaluated using a Thiobarbituric Acid Reactive Substances (TBARS) assay kit 
(Cayman #10009055) and the experiments were performed in adipose tissue 
protein lysates and plasma according to the manufacturer‘s instructions. The 
reaction between thiobarbituric acid (TBA) mix and malondialdehyde from 
samples formed the MDA-TBA adduct under high temperature and acidic 
conditions (Figure 2.2). 
 
Figure 2.2. Determination of TBARS levels 
 
The reaction produced a pink colour which was measured colorimetrically at 
530-540nm. The density of the colour is directly proportional to the amount of 
MDA in the sample. The levels of MDA in the samples were estimated using the 
linear equation obtained from the MDA standard curve provided by the 
manufacturer. 
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2.9 Statistical analysis  
Tissue samples were each analysed in duplicates with 10 mice in each group. 
Cell experiments for lucigenin and amplex red had an n=8 while aldosterone and 
cortisol measurements had an n=7. Statistical comparison of multiple groups 
with one factor variance was analysed using one-way-ANOVA followed by the 
Newman-Keuls post-test. Statistical comparison of multiple groups with a two 
factor variance was analysed using two-way-ANOVA followed by Bonferonni‘s 
multiple correction test. All statistical analysis was carried out with Micosoft 
Excel and Graphpad prism 6 commercially available software. Significance 
threshold for all analysis was considered at p value < 0.05. 
2.10 Drugs and solutions 
2.10.1 Agonists and inhibitors 
Angiotensin II was purchased from Bachem (Torrance, CA, USA). IBMX, insulin, 
dexamethasone, Tempol and ML171 were purchased from Sigma-Aldrich 
Chemical, Co. GKT137831 was supplied by Genkyotex (Switzerland, Geneva). 
Dexamethasone was dissolved in 100% ethanol. GKT137831 and ML171 were 
dissolved in dimethylsulfoxide (DMSO). Ang II and tempol were dissolved in 
distilled water. Insulin was dissolved in 0.01N HCl. 
 
2.10.2 Lucigenin solutions 
ROS Phosphate buffer, pH7.4 in 100 ml dH2O 
1.36g 50mM KH2PO4 with 0.076g 1mM EGTA and 10.26g 150mM sucrose. 
ROS lysis buffer 
10ml of ROS Phosphate buffer, pH7.4, 10µl of 1µg/ml Aprotinin/Pepstatin/ 
Leupeptin respectively and 100µl PMSF 1mM. 
Basal reading mix per well 
50µl sample, 100µl ROS Phosphate buffer, pH7.4 and 75µl lucigenin mix  
Lucigenin mix per well 
73.75µl ROS Phosphate buffer, pH7.4 with 1.25µl lucigenin (10-3M diluted in 
dH2O) 
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2.10.3 Software 
Simplicity 4.2 reference 
ImageJ 
Cell^D from Olympus 
Graphpad Prism 6 
Microsoft Word Excel   
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3 Results 
3.1 Metabolic, biochemical parameters and blood 
pressure in obese db/db mice. 
Obese db/db mice displayed higher body weight compared to lean db/+ controls 
(Figure 3.1A). This was associated with increased epididymal visceral adipose 
tissue (EVAT) mass (Figure 3.1B) and adipocyte hypertrophy as evidenced by 
histological analysis of EVAT sections (Picro-sirius red staining discussed below). 
Treatment with Nox1/4 inhibitor did not reduce body weight, whereas visceral 
adiposity, as measured by EVAT mass, showed a strong tendency (p value = 
0.054) to be reduced in db/db mice treated with the high dose of Nox1/4 
inhibitor (Figure 3.1B). 
 
Obese db/db mice displayed features of metabolic syndrome where glucose, 
total cholesterol, HDL, LDL and triglycerides plasma levels were increased 
compared to lean db/+ control mice (Figures 3.2A-E). These were not 
attenuated by the Nox1/4 inhibitor. Plasma glucose levels of db/db mice were 
elevated versus db/+ controls, however still below 15mmol/L plasma glucose 
and thus could be labelled as mildly diabetic. The C57/bl6 background of this 
mouse model is known to cause a certain resistance to the development of 
diabetes. 
 
Plasma levels of sodium, potassium and other electrolytes were determined in 
obese and lean mice. Plasma chloride levels in db/db mice were decreased 
compared to db/+ mice. Serum levels of potassium, calcium, magnesium and 
phosphate were increased in obese db/db mice versus lean db/+ control mice. 
Nox1/4 inhibition decreased plasma potassium in obese db/db mice versus non 
treated db/db mice, and interestingly increased plasma sodium levels and 
decreased plasma potassium levels in lean db/+ mice at high dose treatment. 
These results may have been caused by slight renal impairment.  
 
Obese db/db mice displayed microalbuminuria (Figure 3.4A) compared with 
lean db/+ mice, indicating significant renal dysfunction Nox1/4 inhibition did not 
reduce microalbuminuria. Blood pressure was similar in db/db and db/+ mice, 
without effect of GKT (Figure 3.4B).   
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Figure 3.1. Obese db/db mice displayed reduced visceral adiposity by Nox1/4 inhibitor 
(GKT137831). Body weight (A) and EVAT adiposity (B) in db/db obese and db/+ lean mice 
treated or not with Nox1/4 inhibitor (GKT137831). Values are means±sem, n=10 mice per group; 
**** p<0.0001, two-way ANOVA followed by Bonferonni‘s multiple test.; + p<0.05 vs db/db NT. 
(NT: No treatment) 
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Figure 3.2. Obese db/db mice were not diabetic but displayed features of metabolic 
syndrome. Plasma levels of glucose, cholesterol, HDL, LDL and triglycerides in in db/db obese 
and db/+ lean control mice treated or not with Nox1/4 inhibitor (GKT137831). Values are 
means±sem, n=10 mice per group. *** p<0.001, **** p<0.0001, two-way ANOVA followed by 
Bonferonni‘s multiple comparison test. (NT: No Treatment)  
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Figure 3.3. Plasma levels of electrolytes in db/db obese and db/+ lean control mice treated 
or not with Nox4/1 inhibitor (GKT137831). Levels of sodium (A), potassium (B), chloride (C), 
calcium (D), magnesium (E) and phosphates (F) in plasma serum from obese db/db and lean db/+ 
mice treated or not with Nox1/4 inhibitor (GKT137831). Values are means±sem, n=10 mice per 
group. * p<0.05, ** p<0.01, **** p<0.0001 two-way ANOVA followed by Bonferonni‘s multiple 
comparison test; + p<0.05 vs db/db NT, # p<0.05 vs db/+ NT. (NT: No Treatment)  
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Figure 3.4. Microalbuminuria and Blood Pressure. Microalbuminuria (A) and blood pressure (B) 
in obese db/db mice and lean db/+ mice treated or not with Nox1/4 inhibitor (GKT137831). 
Values are means±sem, n=10 mice per group. **** p<0.0001, two-way ANOVA followed by 
Bonferonni‘s multiple comparison test. (NT: No Treatment) 
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3.2 Aldosterone and corticosterone concentrations in 
plasma and adipocyte conditioned media were increased 
in obese db/db mice. 
Circulating levels of aldosterone are increased in obese individuals (Goodfriend 
et al, 1999; Krug et al, 2008; Stiefel et al, 2011) and in different animal models 
of obesity (Guo et al, 2008). In addition, high levels of aldosterone have been 
positively correlated with high body mass index (Rossi et al, 2008). The Touyz 
laboratory previously demonstrated that adipocytes express all the components 
of the renin-angiotensin-aldosterone system (RAAS) including the aldosterone 
synthase gene Cyp11b2, and secrete aldosterone, an effect enhanced in obesity 
(Briones et al, 2012). We sought to study the possible implication of Nox-derived 
ROS in aldosterone production by AT as it was recently shown in vitro in 
adrenocortical cells (Rajamohan et al, 2012). Thus, aldosterone levels were 
measured by ELISA Kit in plasma and mature adipocytes culture media from 
db/db obese and db/+ lean mice treated with or without Nox1/4 inhibitor. 
Obese mice displayed a two-fold increase in plasma aldosterone levels compared 
to lean controls (Figure 3.5A). Low and high dose of Nox1/4 inhibitor decreased 
the production to the same capacity. To assess the local production of 
aldosterone, mouse mature adipocytes were isolated from EVAT and cultured for 
24 hours. Levels of aldosterone were determined in culture media concentrated 
five times. Aldosterone levels were increased five-fold in mature adipocytes 
medium (MAM) from db/db obese mice compared to db/+ lean controls. It was 
completely prevented by Nox1/4 blockade in a dose dependent manner (Figure 
3.5B). Whether Nox-derived ROS regulates aldosterone-induced effects in 
adipocytes is the next question we wished to address.  
Determining corticosterone levels was of interest as it precedes aldosterone in 
the steroid hormones synthesis pathway as well as shares an equal selectivity for 
the mineralocorticoid receptor (MR). In MAM from obese db/db mice, 
corticosterone levels were five-fold higher than in MAM from db/+ lean controls. 
Interestingly, Nox1/4 inhibition had no effect on corticosterone levels (Figure 
3.5C). Therefore, Nox1/4-derived ROS does not seem to impact on 
corticosterone secretion by adipocytes.  
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Figure 3.5. Aldosterone and Corticosterone levels in plasma and mature adipocytes media 
(MAM). Aldosterone (A, B) and corticosterone (C) concentrations were determined by ELISA in 
obese db/db and lean db/+ mice. Levels in MAM were normalised by the amount of RNA. Values 
are means±sem, n=10 mice per group. ** p<0.01, **** p<0.0001; two-way ANOVA followed by 
Bonferonni‘s multiple comparison test; ++ p<0.01, ++++ p<0.0001 vs db/db NT. (NT: No 
Treatment) 
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3.4 Nox1/4-derived ROS regulated mRNA levels of 
aldosterone synthase, markers of MR activation and 
selective enzymes for aldosterone/MR in perivascular 
adipose tissue from obese db/db mice. 
Aldosterone synthase Cyp11b2 mRNA levels showed a tendency to increase (p 
value = 0.0934) in PVAT from obese mice compared to lean controls. The levels 
were normalised in obese mice treated with Nox1/4 inhibitor (Figure 3.6A). 
Moreover, mRNA levels of Cyp11b1, the enzyme responsible for corticosterone 
synthesis, were decreased in obese db/db mice and unchanged by Nox1/4 
inhibition (Figure 3.6B). These results support the concept that aldosterone 
concentration is regulated by Nox1/4-derived ROS through regulation of the 
aldosterone synthase gene, but not corticosterone levels. MR gene expression 
was decreased in obese animals (Figure 3.6C). However, mRNA levels of 
different markers of MR activation, Sgk1 and Ngal (or lipocalin-2), were elevated 
in obese db/db mice compared to db/+ lean mice. Nox1/4 inhibition further 
increased Ngal mRNA levels in db/db mice; Sgk1 gene expression was increased 
in db/db but not in db/+ mice (Figures 3.6D and 3.6E). In addition, mRNA levels 
of the glucocorticoid inactivating enzyme 11βhsd2 were decreased in obese 
db/db compared to lean control mice. Interestingly, the high dose of Nox1/4 
inhibitor normalised it (Figure 3.6F). Thus, Nox1/4 inhibition seems to promote 
the inactivate state of corticosterone and potentially promote the action of 
aldosterone through MR rather than corticosterone in obese mice. On the other 
hand mRNA levels of 11βhsd1, the glucocorticoid activating enzyme, were not 
different between db/db and db/+ non treated mice (Figure 3.6G). 
Interestingly, Nox1/4 inhibition decreased both 11βhsd1 and 11βhsd2 mRNA 
levels in lean db/+ mice. 
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Figure 3.6. mRNA levels analysis by real time PCR. Cyp11b2 (A), Cyp11b1 (B) enzymes, 
mineralocorticoid receptor (C) and markers of MR activation (Sgk1 and Ngal) (D, E), 
glucocorticoid inactivating 11βhsd2 (F) and activating 11βhsd1 (G) enzymes were determined. 
Values are means±sem, n=10 mice per group. * p<0.05, ** p<0.01,*** p<0.001,**** p< 0.0001, two-
way ANOVA followed by Bonferonni‘s multiple comparison test; # p<0.05 vs db/+ NT, + p<0.05, 
++ p<0.01 vs db/db NT. (NT: No Treatment)  
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3.3 Increased adipose oxidative stress in obese db/db 
mice.  
Clinical and experimental studies reported that obesity is associated with 
elevated ROS levels and oxidative damage (Furukawa et al, 2004; Hirao et al, 
2010; Fernandez-Sanchez et al, 2011). We evaluated ROS generation in non-
treated and treated animals. In EVAT from obese db/db mice TBARS levels were 
elevated, a marker of lipid peroxidation, indicating systemic increase of 
oxidative stress. This was not reduced by Nox1/4 inhibition (Figure 3.7A). TBARS 
and H2O2 levels in PVAT from obese db/db mice were not different from lean 
db/+ controls (Figure 3.7B) Interestingly, H2O2 levels were enhanced in PVAT 
from db/+ mice when treated with high dose of Nox1/4 inhibitor while treated 
db/db mice levels were unaffected (Figure 3.7C).  
 
3.4 Gene expression of Nox 1, 2 and 4 is differentially 
regulated in perivascular adipose tissue (PVAT) from 
db/db obese mice. 
Nox4 and Nox2 mRNA levels were increased, whereas Nox1 mRNA levels were 
decreased in db/db obese mice compared to db/+ lean mice (Figures 3.8A-C). 
GKT treatment in db/db mice showed a tendency to increase PVAT Nox4 mRNA 
levels at high dose (p value = 0.058) with no effect on Nox1 gene expression. 
Indicating a feed forward system where Nox1/4 inhibition promotes Nox4 and 
Nox2 expression. 
 
3.5 Role of Nox1/4-derived ROS on adipocyte 
differentiation and adipokine expression.  
mRNA levels of adiponectin (adipoq), an adipocyte-specific anti-inflammatory 
mediator, (Figure 3.9A) were decreased in PVAT of obese db/db mice compared 
to lean db/+ mice while levels of Ppar-γ (important in adipocyte maturation) 
remained unchanged (Figure 3.9B). Nox1/4 inhibition had no effect on 
adiponectin and ppar-γ mRNA levels. Adipocyte protein aP2, another 
adipogenesis marker was increased in obese db/db mice compared to lean db/+ 
mice. Treatment had no effect (Figure 3.9C).  
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Figure 3.7. Obese db/db mice displayed systemic and adipose oxidative stress. Systemic 
oxidative stress was evaluated by TBARS in EVAT (A) and in PVAT (B) from obese db/db and lean 
db/+ mice. Hydrogen peroxide (H2O2) levels were determined in PVAT by Amplex Red. Values are 
means±sem, n=10 mice per group. **** p< 0.0001, two-way ANOVA followed by Bonferonni‘s 
multiple comparison test, # p<0.05 vs db/+ NT. (NT: NoTreatment) 
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Figure 3.8. NADPH oxidase isoforms mRNA levels by real time PCR. Nox4 (A), Nox1 (B) and 
Nox2 (C) gene expression were determined. Values are means±sem, n=10 mice per group * 
p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001, two-way ANOVA followed by Bonferonni‘s multiple 
comparison test, + p<0.05 vs db/db NT. (NT: No Treatment) 
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Figure 3.9. Adipokines and adipocyte differentiation markers mRNA levels in db/db mice. 
Adipoq (adiponectin) (A) Ppar-γ (B) and Ap2 (C) mRNA levels in obese db/db and lean db/+ mice 
were determined by Real Time PCR. Results were normalised to IPO8/FBLX10 used as 
housekeeping genes. Values are means±sem, n=10 mice per group. ** p<0.01, two-way ANOVA 
followed by Bonferonni‘s multiple comparison test # p<0.05 vs db/db NT. (NT: No Treatment) 
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3.6 Fibrosis in visceral adipose tissue from db/db obese 
mice is not attenuated by Nox1/4 inhibition. 
During adipose tissue expansion, the extracellular matrix requires remodelling to 
accommodate adipocyte growth. Here, we assessed general upregulation of 
several extracellular matrix components in adipose tissue in the ―obese‖ state, 
therefore implicating ―adipose tissue fibrosis‖ as a hallmark of metabolic 
dysfunction. Collagen VI is a highly enriched extracellular matrix component of 
adipose tissue. Moreover, it is known that aldosterone has pro-fibrotic effects in 
several target tissues (kidney, heart, vessels) in the context of metabolic 
syndrome (Krug et al, 2008; Essick et al, 2011). Thus we questioned if Nox1/4 
inhibition is able to impact on aldosterone-induced deleterious effects in adipose 
tissue. 
 
Obese db/db mice presented higher mRNA levels of collagen 6a in PVAT than 
lean db/+ mice (Figure 3.11A), which is not affected by Nox1/4 inhibition. 
Collagen content in EVAT was measured by polarized light microscopy and 
quantified by image-analysis software and showed an increase in obese db/db 
versus lean db/+ mice (Figures 3.11B and C). From the picro Sirius red slides 
the collagen levels in EVAT from db/db mice seem to reduce with Nox1/4 
inhibitor but the changes where not statistically significant. However, the 
difference between db/+ NT mice and db/db low dose treated mice was lost (p 
value= 0.820) and thus indicates a mild reduction in collagen levels (Figure 
3.11C). 
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Figure 3.10. Obese db/db mice displayed adipose tissue fibrosis. Col6a (collagen 6a) (A) mRNA 
levels were assessed by real time PCR in PVAT from obese db/db and lean db/+ mice. Results 
were normalised to IPO8/FBLX10 housekeeping genes. EVAT collagen content (B-C) were 
visualised by polarized light microscopy and quantified using image analysis software (D) Picro-
sirius red stained EVAT slides. The single head arrows indicate collagen, an index of adipose 
tissue fibrosis in db/db mice. Double head arrow indicates diameter of adipocytes, showing 
larger size (hypertrophy) in db/db mice versus controls. Values are means±sem, n=10 mice per 
group. **** p<0.0001, two-way ANOVA followed by Bonferonni‘s multiple comparison test. (NT: 
No Treatment) 
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3.7 Effects of Nox1/4 inhibitor on visceral fat 
inflammation and macrophage polarisation in obese mice. 
Since obesity is associated with chronic low-grade inflammation of adipose 
tissue, where both adipocytes and macrophages contribute to local inflammation 
as well as promoting further inflammatory activity from each other, we sought 
to investigate changes in expression of specific markers of macrophages in PVAT 
from obese and lean mice.  
 
F4/80 mRNA levels were increased in PVAT from obese db/db mice compared to 
lean db/+ controls, an effect that was not changed by Nox1/4 inhibition (Figure 
3.12A). These results indicate that macrophages are more abundant within 
adipose tissue from obese mice than from lean mice. However, this does not 
differentiate between macrophages type 1 (M1, pro-inflammatory) and type 2 
(M2, anti-inflammatory). Thus, we analysed mRNA levels of markers for M1 and 
M2 macrophages by real time PCR. 
 
3.7.1 Classically activated (M1) macrophages markers 
iNOS mRNA levels demonstrated a tendency to increase in PVAT from obese 
db/db mice (p value = 0.068), an effect normalised with high dose of Nox1/4 
inhibitor (Figure 3.12B). TNF-α mRNA levels were increased in db/db obese 
mice and treatment had no effect (Figure 3.12C). Nox1/4-derived ROS may 
participate in adipose tissue inflammation in obesity, through iNOS-dependent 
signalling pathways and potentially M1 polarisation in PVAT. 
 
3.7.2 Alternatively activated (M2) macrophages markers 
M2 markers Arg1 and CD206 mRNA levels were elevated in PVAT from db/db 
obese mice (Figures 3.12D, 3.12E). The expression of Arg1 in obese mice was 
further enhanced with high dose of Nox1/4 inhibitor. As iNOS and arginase-1 
compete for L-arginine the decrease found in iNOS mRNA levels is further 
supported by the increase in Arg1. Arginase-1 blocks iNOS activation, thus 
preventing nitric oxide production. Fizz1 mRNA levels were decreased in PVAT 
from obese mice, while Il-10 mRNA levels were not significantly different across 
the groups (Figures 3.12F and 3.12G). Nox1/4 inhibition had no effect on 
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CD206, Fizz1 and Il-10 gene expression. Hence, these data suggest that 
inhibition of Nox1/4-derived ROS generation promotes an anti-inflammatory 
phenotype through an increase of arginase1 and a decrease of iNOS. 
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Figure 3.11. Nox1/4 inhibitor (GKT137831) promoted an anti-inflammatory phenotype in 
PVAT from obese db/db mice. mRNA levels of F4/80 (A), M1 markers (B-C) and M2 markers (D-
G) were determined by real time PCR. Values are means±sem, n=10 mice per group. * p<0.05, *** 
p<0.001, **** p<0.0001 two-way ANOVA followed by Bonferonni‘s multiple comparison test, + p< 
0.05 db/db NT. (NT: No Treatment)   
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3.8 Studies in human SW872 adipocytes: Angiotensin II 
induces aldosterone and cortisol production and ROS 
generation, through NADPH oxidases-dependent 
mechanisms. 
To explore some of the findings in our mouse models in human cells, we studied 
SW872 cells, an adipocyte line resembling white adipocytes. These cells were 
used to assess some mechanisms involved in aldosterone and cortisol production. 
Adipocytes were stimulated with angiotensin II (Ang II, 10-8M) for 24 hours with 
or without Nox1/4 inhibitor (GKT137831, 10-6M), Nox1 inhibitor (ML171, 10-6M) 
and SOD mimetic (Tempol, 10-6M). Levels of aldosterone and cortisol were 
determined by ELISA in culture media.  
 
Figure 3.13A showed that Ang II-induced aldosterone production by adipocytes 
was blocked by tempol, GKT and ML171, while Ang II-induced cortisol production 
was blocked by tempol and GKT, but not ML171 (Figure 3.13B). Therefore, in 
human differentiated adipocytes, Ang II promoted aldosterone in a Nox1/4- 
dependent manner and cortisol in was Nox4-dependent. Figures 3.13 C and D 
show that stimulation for 24h with angiotensin II increased H2O2 and O2
- 
production in human mature adipocytes. H2O2 levels were decreased with GKT 
(Nox1/4 inhibitor) but not by ML171 (Nox1 inhibitor) while O2
- production was 
normalised with both GKT and ML171. Thus, Ang II in differentiated human 
adipocytes induced hydrogen peroxide (H2O2) through Nox4-dependent 
mechanisms and superoxide ions (O2
-) production via Nox1-dependent 
mechanisms. These results support findings in the literature stating that Nox4 
seems to produce H2O2 rather than O2
- unlike other Noxes (Serrander et al, 
2007). 
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Figure 3.12. Angiotensin II enhanced aldosterone and cortisol levels and ROS generation by 
human differentiated adipocytes cell line SW872. Aldosterone (A) and cortisol (B) 
concentrations were determined by ELISA in culture media (CCM) from human differentiated 
adipocytes (SW872) stimulated with Ang II for 24h. Levels were normalised to protein levels. H2O2 
(C) and O2
- production (D) were determined by Amplex red and lucigenin assay respectively. 
GKT137831 1 µmol/L. Values are means±sem, n=7-8 individual sets of experiments. * p<0.05, *** 
p<0.001 vs vehicle, # p<0.05, ## p<0.01 vs AngII, one-way ANOVA followed by Newman-Keuls 
multiple comparison test. (NT: No Treatment) 
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4 Summary of Results 
We hypothesized that in obesity associated with metabolic syndrome, 
adipocytes generate aldosterone through Nox1/4-dependent processes, 
contributing to a pro-inflammatory and pro-fibrotic adipose phenotype. 
 
Aim 1: To evaluate whether obesity/metabolic syndrome is associated with 
hyperaldosteronism and increased adipocyte-derived aldosterone through 
processes that involve Nox1/4. 
- Nox1/4 participates in adipocyte aldosterone production, an effect exacerbated 
in obesity. 
- In Ang II-stimulated human adipocytes, Nox1/4-derived ROS contributes to 
aldosterone production, confirming studies in mouse adipocytes. 
- In Ang II-stimulated SW872 cells, increased ROS generation was normalised by 
Nox1/4 inhibition.  
- In Ang II-stimulated human adipocytes, Nox1/4-derived ROS contributes to 
aldosterone production, confirming studies in mouse adipocytes. 
 
Aim 2: To determine whether increased Nox1/4-derived ROS influences 
aldosterone biosynthesis by stimulating aldosterone synthase in adipocytes.  
- Aldosterone production is regulated by Nox1/4 at the gene level via aldosterone 
synthase. 
- Corticosterone synthesis by adipocytes was not Nox1/4 dependent however, the 
gene expression of the glucocorticoid regulating enzymes were. 
- MR signalling markers and ROS generation were increased in obese animals. 
 
Aim 3: To assess whether aldosterone and ROS promote adipokine production 
and adipogenesis and if this is increased in obesity, and  
Aim 4: To elucidate whether redox-sensitive processes and aldosterone promote 
a pro-inflammatory and pro-fibrotic adipose phenotype. 
- In obese animals the anti-inflammatory adipokine, adiponectin was decreased 
while the adipogenic adipokine aP2 was increased. Nox1/4 inhibitor had no 
effects on adiponectin levels but normalised aP2 levels. 
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- Nox1/4 inhibitor promoted the polarisation of macrophages towards an anti-
inflammatory phenotype in obese db/db mice. 
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5 Discussion 
Metabolic syndrome – model of obesity used 
Leptin is secreted from fat cells and acts on the hypothalamus to suppress the 
appetite and thus regulates food intake and energy expenditure. The leptin 
receptor deficiency (homozygous mutation of the leptin receptor (Leprdb)) in 
db/db mice leads to morbid obesity by preventing the homeostatic control of 
adipose tissue mass by leptin. Mice model, B6.BKS(D)-Leprdb/J, used had a 
premature termination of the long cellular domain of the leptin receptor Ob-Rb 
splice form leading to the loss of its signal transducing function. In mice, the 
leptin receptor is alternatively spliced into five isoforms: Ob–Ra, Ob–Rb, Ob–Rc, 
Ob–Rd, and Ob–Re (Lee et al, 1996). Ob–Rb is the longest isoform expressed at 
high level in the hypothalamus and at lower level in other tissues including: 
testes, adipose tissues, pancreatic b cells, heart, lung, and lymph nodes (Fei et 
al, 1997; Lollmann et al, 1997). The inbred C57BL/6 genetic background 
arbitrated the severity of the disease by suppressing the otherwise spontaneous 
diabetic phenotype. Hence, the mice were morbidly obese and pre-diabetic with 
elevated glucose levels but would have required to be challenged in order to 
become diabetic (Hummel et al, 1972; Clément et al, 1998). The C57BL/6 
background leads to compensatory hyperplasia of pancreatic islet beta with 
elevated plasma insulin as well as glucose levels starting from 10-14 days and 16 
weeks respectively. Affected mice are polyphagic, polyuric and polydipsic (The 
Jackson laboratory, 2014; Clément et al, 1998). They also show 
hypercortisolaemia, dyslipidaemia and infertility due to hypogonadotropic 
hypogonadism (Coleman, 1978). The phenotype displayed by the db/db model is 
found in humans as a rather rare mutation in leptin or the leptin receptor 
genes(Farooqi et al, 2002). This disease model is reflected in humans only in 
rare genetic cases causing a genetic leptin deficiency while obesity is a form of 
leptin resistance and not an absolute lack off (Friedman, 2009). 
The db/db mice model used exhibited features of metabolic syndrome as 
evidenced by elevated plasma levels of glucose, triglycerides and cholesterol 
(Figures 3.2 and 3.3). As expected, body weight of obese mice was greater than 
lean controls. The Nox1/4 inhibitor GKT137831 had no effect on body weight, 
but significantly reduced EVAT adiposity of db/db mice, suggesting an effect on 
white adipose tissue mass (Figure 3.1). Visceral fat depots have lower 
Sarah Even   68 
 
hyperplasic capacity than other fat pads (DiGirolamo et al, 1998) resulting in 
greater stress on visceral than subcutaneous adipocytes in obesity. Adipocytes 
become hypertrophic and more rigid, as seen in our study where adipocytes in 
db/db mice were increased in size with increased fibrosis, thus reducing their 
capacity to expand with increased lipid uptake. Elevated plasma potassium in 
obese db/db mice was associated with high levels of plasma and adipocyte-
derived aldosterone. Interestingly, the release of aldosterone is known to be 
stimulated by high potassium concentrations, while infusion of aldosterone 
lowers plasma potassium. Upon treatment with GKT, potassium and aldosterone 
levels were decreased. This may be due to the renoprotective effects of GKT in 
the kidney in db/db mice (Jha et al, 2014; Thallas-Bonke et al, 2015, Briones et 
al, 2012). 
 
Role of Nox1/4 in adipocyte-aldosterone synthesis in obesity 
Adipocytes possess Nox1, Nox2 and Nox4. The function of these Nox isoforms in 
adipose tissue is unclear. Our data demonstrate that Nox1/4 inhibition 
(GKT137831) reduces adipocyte-derived aldosterone production and 
inflammation in obesity. This suggests a key role for Nox1/4 in aldosterone 
biosynthesis and function in adipocytes. Our findings in adipose tissue were 
further supported by results obtained related to aldosterone levels in adipocyte 
conditioned media and in plasma from obese mice. To further explore the 
relationship between aldosterone, ROS and Noxs in adipocytes, we performed in 
vitro studies in human adipocytes (SW872), stimulated with angiotensin II in the 
absence and presence of the Nox inhibitor. Findings from these studies 
confirmed a role for Nox1/4 in ROS-mediated aldosterone production in Ang II-
stimulated adipocytes. 
 
From the systemic and local decrease in aldosterone concentrations caused by 
the Nox1/4 inhibitor, GKT137831, in mice, adipose tissue and cultured 
adipocytes, we could argue that aldosterone production by adipocytes is a 
Nox1/4-dependent process. Similar findings were observed in adrenal cells. 
Rajamohan et al (2012) demonstrated that Nox-derived hydrogen peroxide 
participates in Ang II-induced aldosterone production in adrenocortical cells. 
Hence adipocytes may share common redox-sensitive aldosterone-producing 
pathways as adrenal cells. Adipocyte-derived aldosterone production was 
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decreased in a dose dependent manner while plasma aldosterone was not 
further decreased by high dose of the Nox1/4 inhibitor. The adrenal gland (AG) 
is known to be the main source of aldosterone. However, due to its interaction 
with AT and the production of aldosterone by the AT one may wonder if, in 
obesity, the AT participates in systemic aldosterone levels. The increase in 
adipocyte number (hyperplasia) and size (hypertrophy) could further promote 
aldosterone production in obesity. Furthermore, AT stimulates release of AG-
derived aldosterone via mineralocorticoid-releasing factors (Ehrhart-Bornstein et 
al, 2003). Thus, in obesity AT may participate in peripheral aldosterone actions.  
All components of the RAAS are expressed in adipose tissue along with the AT1R, 
AT2R, renin, mineralocorticoid and glucocorticoid receptors. In obesity, adipose 
RAAS is over-activated and thus may participate in metabolic syndrome along 
with aldosterone/MR activation (Kulapahana & Mustaid-Mussa, 2012; Rahmouni 
et al, 2004). 
 
To assess the significance of adipocyte-derived aldosterone and its specific 
physiopathological role in obesity, the study of a transgenic mouse model with 
adipocyte-specific aldosterone synthase deletion on a high fat diet would be 
relevant as well as obese db/db mice submitted to adrenalectomy. These studies 
would help elucidate what component of aldosterone is adrenal-independent. 
In obesity, Nox1/4-derived ROS promote adipocyte-aldosterone synthesis and 
could induce AT damage such as fibrosis and inflammation, and this may be 
through aldosterone-dependent signalling pathways. The effects of Nox1/4-
derived ROS on aldosterone production may trigger a vicious circle as 
aldosterone has been shown to promote oxidative stress as well. ROS feeds into 
aldosterone production and vice versa leading to a vicious feedforward circle. 
This may contribute to the overall increase in AT dysfunction and inflammation 
in obesity. 
 
Role of Nox1/4 in Mineralocorticoid signalling in obesity 
The mineralocorticoid receptor (MR) gene expression in adipose tissue was 
decreased in obese db/db mice. However, the gene expression of MR activation 
markers (Sgk1 and Ngal) was increased, indicating augmented MR signalling in 
obese db/db mice. Nox1/4 inhibition increased Ngal and had no effect on Sgk1 
gene expression. Ngal also known as lipocalin-2 is associated with a variety of 
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diseases as well as promoting antioxidant enzymes superoxide dismutase (SOD) 
and heme oxygenase (HO-1) gene expression (Bahmani P et al, 2010). GKT may 
promote antioxidant effects of Ngal, thus reducing oxidative stress occurring in 
obesity. Moreover, high levels of corticosterone in obese mice were unaltered by 
GKT, suggesting a targeted action of GKT treatment on aldosterone production. 
We cannot exclude the possibility that MR may also be activated by 
glucocorticoids (GCs). GCs exert pleiotropic effects on adipocyte metabolic, 
endocrine and immune functions and may explain why GKT did not completely 
decrease inflammation and had little effects on fibrosis in adipose tissue from 
db/db mice, despite reduced aldosterone production. Future studies will 
evaluate the GC/GC receptor in adipocytes in obesity and the role of Nox-ROS. 
 
Nox1/4 and ROS production in adipocytes in obesity  
NADPH oxidase (Nox)-derived reactive oxygen species (ROS) have been 
implicated in adipocyte biology including adipogenesis and adipocyte 
differentiation (Mouche et al, 2007; Schröder et al, 2009; Liu et al, 2012). Noxes 
tend to be upregulated in AT from obese mice (Furukawa et al, 2004). 
In our study only the phagocytic Nox2 mRNA levels were increased in adipose 
tissue from obese db/db mice. This may be due to macrophage infiltration in 
adipose tissue in obesity, which contributes to adipose inflammation (Figure 
3.8c). As Nox4 is a constitutively active enzyme, its gene expression is expected 
to reflect changes in protein levels (Serrander et al, 2007). It would be of 
interest to determine Poldip2 levels of expression and co-localisation with Nox4. 
Lyle et al (2009) demonstrated that Poldip2 co-localizes with Nox4 and Nox1 at 
p22phox at sites in SMCs and enhances Nox4 –ROS production by three-fold. Nox1 
mRNA levels in EVAT were not different across the groups and were decreased in 
PVAT from db/db NT mice compared to controls.  
In the present study there were some disparities in oxidative stress between fat 
depots, EVAT and PVAT. Obese db/db mice displayed elevated TBARs in EVAT 
while PVAT TBARS and hydrogen peroxide levels were not significantly different 
from the lean control mice. These data indicate that differences in redox status 
exist between adipose tissue depots and their contribution to metabolic 
complications may be different. It is also possible that different types of 
adipocytes (white, brown or beige) may exhibit different redox state and 
inflammatory phenotype. The lack of decrease in ROS production seen in PVAT 
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from treated db/db mice may also be due to the lower levels of Nox1 gene 
expression in obese mice compared to lean mice. The lack of effect might be 
because there was no increase in ROS/TBARS in PVAT and that blocking Nox1/4 
would have been countered in order to maintain ROS levels. It could have been 
caused by a decrease in antioxidants or increase in other sources of ROS. Thus 
looking into antioxidants as well as the protein levels of the Noxes would be of 
interest. The selectivity of GKT137831 for Nox1/4 may also be questioned even 
if GKT137831 has been used in a few studies as a Nox1/4 inhibitor (Gorin et al, 
2015; Jiang et al, 2012). The effects of GKT can be assessed by the indirect 
means of ROS production as seen in the cell experiments. Mature human 
adipocytes stimulated with angiotensin II for 24h demonstrated that superoxide 
ions O2
- production was decreased with Nox1 and Nox1/4 inhibitors while H2O2 
levels were decreased only with Nox1/4 inhibitor. These results follow the trend 
of thought that Nox4 produces hydrogen peroxide and Nox1 superoxide thus 
showing be indirect measurements that the inhibitors used in the study inhibit 
the expected targets. For further clarity labelling the GKT would permit to see if 
it does specifically bind only to Nox1 and Nox4 in mice which could be of 
interest.  
 
Adipocyte inflammation, fibrosis, aldosterone and ROS in obesity 
Adipose tissue and inflammation  
Several studies have demonstrated in obesity, dysregulation in production of 
pro-inflammatory adipokines such as TNF-α, IL-6, MCP-1 and angiotensinogen, 
and in protective adipokines such as adiponectin and leptin. The underlying 
mechanisms from excess fat storage to AT dysfunction have not yet been fully 
elucidated. Systemic oxidative stress has been shown to be correlated with fat 
accumulation and thus may participate to the development and progression of 
metabolic syndrome (Keaney JF et al 2003; Furukawa et al 2004). Our results 
confirm others by showing a decrease in protective adipokine adiponectin levels 
and increased macrophage infiltration in obese mice. A study by Yamauchi et al 
(2007) showed adiponectin receptor 1 and 2 deficient mice had enhanced 
oxidative stress. While, Furukawa et al (2004) demonstrated that the decreased 
adiponectin levels can be reversed by apocynin, a ROS scavenger. However, in 
our study, inhibition of Nox1/4 did not normalise adiponectin levels in obese 
db/db mice. It is possible that other sources of ROS such as the mitochondria, 
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xanthine oxidase enzymes, endoplasmic reticulum and other Noxes for example 
could affect adiponectin levels. The loss of protective effects by adiponectin 
could have promoted pro-inflammatory cytokine production and possibly insulin 
resistance thus leading to AT damage in db/db mice. 
 
The increase in macrophage marker F4/80 in AT from obese db/db mice indicate 
that obese mice have more macrophages in the AT compared to lean controls. 
On the other hand it does not necessarily indicate the type of macrophage 
polarisation (Figure 3.11A). Macrophages are commonly found in obese as well as 
lean WAT (Feuerer et al, 2009), although the prevalence increases with 
adipocyte hypertrophy (Weisberg et al, 2003). M1 macrophages play a central 
role in innate immunity while M2 macrophages are associated with anti-
inflammatory processes, tissue remodelling and fibrosis (Natoli & Monticelli, 
2014). The M1/M2 ratio would provide indications with regards to the 
inflammatory status of the AT. In obese db/db mice the M1 markers iNOS and 
TNF-α gene expression were elevated and iNOS was normalised by GKT137831. 
M2 markers Arginase-1 and CD206 mRNA levels were elevated and Arginase-1 
was further increased with treatment hinting at a push towards M2 type 
polarisation of macrophage with GKT treatment. IHC complementary studies 
would enable us to determine if there are crown like structures indicating 
increased adipocyte cell deaths and further AT dysfunction (Cinti et al, 2005). 
Whether the changes in macrophage polarisation are due to Nox1/4-derived ROS 
or aldosterone, or both, cannot be determined from these experiments. In vitro 
experiments using culture media from differentiated adipocytes stimulated with 
aldosterone along with GKT to stimulate monocytes would be further studies to 
determine the effects specific to aldosterone on differentiation of these 
stimulated monocytes into macrophages. Further more FACS experiments and 
protein levels would be of interest and give stronger information on the status of 
macrophage polarisation than mRNA levels. 
 
Adipose tissue and fibrosis 
Fibrosis is an important feature in dysfunctional adipose tissue in obesity. 
Previous studies demonstrated that Nox1/4 plays an important role in fibrosis in 
various organs, e.g. liver, kidney, vessels, effects that are blocked with 
GKT137831 (Aoyama et al, 2012; Babalola et al, 2014; Jiang et al, 2012). 
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Whereby, the semi-quantitative analysis of Picro Sirius red stained collagen with 
thick fibres (collagen I) was seen as an orange/red colour compared to collagen 
with thinner fibres (collagen III) had green/yellow colours. Divoux et al (2010) 
demonstrated a build-up of thick fibres (Red coloured collagen) in AT of obese 
subjects leading to the focus on red coloured collagen seen via polarised light 
microscopy. From the Picro-Sirius Red staining and the polarised microscopy 
data, we showed pronounced remodelling in AT from obese mice indicated by 
the increase in fibrillary collagen content in obese mice compared to lean 
controls (Figure 3.10). Obese treated mice did not show a significant decrease in 
thick fibered collagen contents. We also assessed collagen 6 levels as studies on 
ob/ob mice lacking collagen 6 have demonstrated significantly improved glucose 
metabolism and lacking fibrotic depots (Khan et al, 2009). Collagen 6 gene 
expression was enhanced in obese db/db animals as seen in other studies. 
However the treatment had no effect. Rather than affecting collagen 6, Nox1/4 
role may impact on other collagens or matrix metalloproteinases which have the 
capacity to degrade the extracellular matrix.  
 
Translating findings to human adipocytes 
From the in vitro studies we showed that adipocyte-derived aldosterone 
production is Nox1/4 dependent while adipocyte-cortisol production is Nox4-
dependent in human adipocytes. These data are in line with the mouse studies 
and highlight a potentially important role for Nox1/4 in adipose biology, 
especially in conditions associated with obesity and hyperaldosteronism. Nox1/4 
may be an interesting therapeutic target in obese patients with associated 
hyperaldosteronism. 
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General conclusion 
Obesity is a global problem that is reaching pandemic proportions. It is a major 
contributor and risk factor for metabolic and cardiovascular diseases. Central to 
the development of obesity is adipose tissue – a dynamic and metabolically 
active organ. Thus, it is necessary to understand the mechanisms leading to 
adipose tissue dysfunction in obesity. Compelling experimental evidence 
indicates that ROS and hyperaldosteronism are elevated in adipose tissue in 
obesity and may participate in obesity associated inflammation leading to 
metabolic and cardiovascular diseases. In this study we explored molecular 
mechanisms whereby adipocytes become pro-inflammatory and pro-fibrotic in 
obesity, focusing on the role of Nox-derived ROS and aldosterone.  
Our findings demonstrate that in a mouse model of obesity:  
- Nox1 and Nox4 participate in adipocyte aldosterone production. 
- Nox1/4 inhibition decreased epididymal visceral fat adiposity. 
- Adipose tissue ROS levels differ between fat depots. 
- Nox1/4 inhibition had a tendency to decrease fibrosis and promote 
macrophage polarization towards an anti-inflammatory phenotype. 
In conclusion our novel findings highlight an important role for Nox1 and Nox4 in 
adipocyte-derived aldosterone production and inflammation in obesity. Thus, 
Nox1/4 inhibition may be a putative therapeutic target in obesity associated 
hyperaldosteronism and associated cardiovascular disease. 
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